Stem cell shot for frailty? early safety trial begins
NCT ID NCT07462819
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests whether a stem cell product called Stemis™ is safe for older adults with mild to moderate frailty. Frailty causes weakness, slow walking, and reduced daily function, with no approved treatments. Around 12 people aged 60–85 will receive either Stemis™ or a placebo, and researchers will monitor for side effects and explore changes in strength and mobility.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stemis™ (human umbilical cord-derived mesenchymal stem cells)
What this could lead to
If safe, this could pave the way for larger studies exploring whether stem cells can ease frailty symptoms like weakness and slow walking.
What could go wrong
This is a very early, small Phase 1 trial with only 12 people. It is designed to check safety, not effectiveness, so it may not lead to any treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAILTY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Taipei Medical University Hospital
Taipei, Taiwan